Clene (CLNN) vs Xilio Therapeutics (XLO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Xilio Therapeutics (XLO) has outperformed Clene (CLNN) over the past year, losing 28.3% versus a loss of 62.0%. Over five years, CLNN leads with a -96.3% price change compared with -97.3% for XLO. Xilio Therapeutics is the larger company by market cap ($53.4 million vs $50.7 million), about 1.1 times the size.
Xilio Therapeutics converts more of its revenue into profit, with a net margin of -80.1% versus -13086.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLNN | XLO |
|---|---|---|
| Share price | $3.52 | $7.56 |
| Market cap | $50.69M | $53.40M |
| 1-day change | +0.57% | -1.11% |
| YTD return | -40.03% | -15.63% |
| 1-year return | -62.03% | -28.29% |
| 5-year return | -96.28% | -97.29% |
| P/E ratio (TTM) | — | 11.63 |
| EPS (TTM) | $-2.30 | $0.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $200.00K | $43.77M |
| Revenue growth (YoY) | -41.52% | +589.88% |
| Net income (latest FY) | $-26.17M | $-35.04M |
| Gross margin | 78.50% | — |
| Operating margin | -11541.50% | -95.92% |
| Net margin | -13086.50% | -80.05% |
| 52-week high | $10.84 | $10.71 |
| 52-week low | $3.02 | $6.47 |
| Distance from 52-week high | -67.53% | -29.41% |
| Analyst consensus | none | none |
| Avg. price target upside | +814.77% | +164.55% |
| Average volume | 115.06K | 11.54K |
| Shares outstanding | 14.40M | 7.06M |
| Employees | 76 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XLO has outperformed CLNN by 33.7 percentage points over the past year.
- Xilio Therapeutics is more profitable, keeping -80.1 cents of every revenue dollar as net income versus -13086.5 cents for Clene.
- Xilio Therapeutics grew revenue faster in its latest fiscal year (+589.88% vs -41.52%).
About Clene
CLNN stock →Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Xilio Therapeutics
XLO stock →Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
CLNN vs XLO FAQ
Which is bigger, Clene or Xilio Therapeutics?
Xilio Therapeutics (XLO) is larger, with a market capitalization of $53.40M compared with $50.69M for Clene (CLNN).
Which stock has performed better over the past year, CLNN or XLO?
XLO returned -28.29% over the past 12 months, compared with -62.03% for CLNN (price return, excluding dividends). Past performance does not predict future results.
Are Clene and Xilio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.